EP0975593A1 - Derives indoliques a activite de recepteur antagoniste 5ht1a, 5ht1b, 5ht1d - Google Patents

Derives indoliques a activite de recepteur antagoniste 5ht1a, 5ht1b, 5ht1d

Info

Publication number
EP0975593A1
EP0975593A1 EP98921462A EP98921462A EP0975593A1 EP 0975593 A1 EP0975593 A1 EP 0975593A1 EP 98921462 A EP98921462 A EP 98921462A EP 98921462 A EP98921462 A EP 98921462A EP 0975593 A1 EP0975593 A1 EP 0975593A1
Authority
EP
European Patent Office
Prior art keywords
indole
dihydro
methylpiperazin
chloro
phenylaminocarbonyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP98921462A
Other languages
German (de)
English (en)
Inventor
Laramie Mary Smithkline Beecham Gaster
Harshad Kantilal SmithKline Beecham RAMI
Paul Adrian Smithkline Beecham Wyman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Ltd
Original Assignee
SmithKline Beecham Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9707829.9A external-priority patent/GB9707829D0/en
Priority claimed from GBGB9801882.3A external-priority patent/GB9801882D0/en
Application filed by SmithKline Beecham Ltd filed Critical SmithKline Beecham Ltd
Publication of EP0975593A1 publication Critical patent/EP0975593A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Definitions

  • the present invention relates to novel piperazine derivatives, processes for their preparation, and pharmaceutical compositions containing them.
  • 5 WO 95/06637, WO 95/06044 and WO 95/04729 disclose a series of piperazine derivatives which are said to possess 5HTIJJ receptor antagonist activity. These compounds are alleged to be of use in the treatment of various CNS disorders such as depression.
  • EPA 0533266/7/8 disclose a series of benzanilide derivatives which are said to possess 5-HTI J receptor antagonist activity.
  • the present invention therefore provides a compound of formula (I) or a salt thereof:
  • R a is a group of formula (i)
  • pi is phenyl, bicyclic aryl, a 5 to 7 membered heterocyclic ring containing 1 to 3 heteroatoms selected from oxygen, nitrogen and sulphur, or a bicyclic heterocyclic ring containing 1 to 3 heteroatoms selected from oxygen, nitrogen and sulphur;
  • 25 R.1 is hydrogen, halogen, C ⁇ .galkyl, C3_6cycloalkyl, COCj.g ⁇ y .
  • R 2 is hydrogen, halogen, C ⁇ alkyl, C ⁇ . ⁇ cycloalkyl, C3_6cycloalkenyl, C ⁇ alkoxy, C ⁇ galkanoyl, aryl, acyloxy, hydroxy, nitro, trifluoromethyl, cyano, CO 2 RlO, CO 10R.11 , NRIORI 1 w here R 10 and R 11 are as defined for R 1 ; a is 1, 2 or 3; or R a is a group of formula (ii)
  • P 2 and P ⁇ are independently phenyl, bicyclic aryl, a 5- to 7- membered heterocyclic ring containing 1 to 3 heteroatoms selected from oxygen, nitrogen and sulphur, or a bicyclic heterocyclic group containing 1 to 3 heteroatoms selected from oxygen, nitrogen or sulphur;
  • A is a bond or oxygen, S(O) m where m is 0 to 2, carbonyl, CH , -CH -CH -, or N ⁇ where R ⁇ is hydrogen or Ci.galkyl; Rl is as defined above for formula (i) or R is a 5 to 7-membered heterocyclic ring, containing 1 to 3 heteroatoms selected from oxygen, nitrogen or sulphur, optionally substituted by C ⁇ . alkyl, halogen or C ⁇ . alkanoyl;
  • R 2 and R ⁇ are independently hydrogen, halogen, Cj.galkyl, C3_6cycloalkyl,
  • Y is -NH-, -NR 5 - where R 5 is C ⁇ alkyl, or Y is -CH - or -O-; V is oxygen or sulphur; D is nitrogen, carbon or a CH group; W is (CR ⁇ Rl7) t where t is 2, 3 or 4 and R ⁇ 0" and Rl7 are independently hydrogen or Ci- ⁇ alkyl or W is (CR ⁇ R17)
  • X is nitrogen or carbon;
  • Rb is hydrogen, halogen, hydroxy, C ⁇ .galkyl, trifluoromethyl, C ⁇ _6alkoxy, C _6alkenyl, C3_7cycloalkyl optionally substituted by C ⁇ alkyl, or aryl;
  • R c is hydrogen
  • C i _6alkyl groups whether alone or as part of another group may be straight chain or branched.
  • the term 'acyloxy' is used herein to describe a group -OC(O)C ⁇ _6alkyl.
  • the term 'aryl' is used herein to describe, unless otherwise stated, a group such as phenyl.
  • the term 'aralkyl' is used herein to describe, unless otherwise stated, a group such as benzyl.
  • the bicyclic aryl group represented by P , P 2 and or P ⁇ , which may be partially saturated, is preferably naphthyl.
  • bicyclic heterocyclic rings containing 1 to 3 heteroatoms selected from oxygen, nitrogen and sulphur include isoquinoline, indole, benzofuran, benzothiophene and preferably quinoline.
  • Examples of 5 to 7 membered heterocyclic rings containing 1 to 3 heteroatoms selected from oxygen, nitrogen and sulphur represented by P , P 2 and/or P- include thienyl, furyl, pyrrolyl, triazolyl, imidazolyl, oxazolyl, thiazolyl, oxadiazolyl, isothiazolyl, isoxazolyl, thiadiazolyl, pyrimidyl, pyridazinyl and pyrazinyl, and preferably pyridyl.
  • heterocyclic rings as described above can be linked to the remainder of the molecule via a carbon atom or, when present, a suitable nitrogen atom. Such rings can also be saturated or partially saturated. Examples of saturated or partially saturated 5 to 7 membered heterocyclic rings include piperidine, pyrrolidine and morpholine. Examples of partially saturated bicyclic heterocyclic rings include dihydrobenzofuran, dihydrobenzothiophene, tetrahydroquinioline and tetrahydroisoquinoline Rl is preferably a halogen atom for example, fluorine, chlorine or bromine, and
  • R 2 and/or R ⁇ are each preferably hydrogen, halogen for example a chloro group, or a C ⁇ _ galkyl group for example a methyl group.
  • suitable optional substituents include C ⁇ . ⁇ alkyl, ⁇ . alkanoyl and halogen.
  • a and b are each preferably 1 or 2.
  • A is preferably a bond or oxygen, most preferably a bond.
  • Y is preferably -NH-.
  • V is preferably oxygen.
  • D is preferably nitrogen and the group W is preferably a (CR ⁇ Rl 7 ) ⁇ group where
  • Rl6 and R* 7 are each advantageously hydrogen and t is suitably 2.
  • R D is preferably hydrogen or a halogen atom for example chlorine, a Cj.galkoxy group for example methoxy or a C ⁇ . ⁇ alkyl group such as methyl or ethyl.
  • X is preferably nitrogen.
  • R c is preferably a Ci- ⁇ lkyl group for example methyl.
  • Particularly preferred compounds according to the invention include :- l-[(4-bromo-3-methylphenyl)aminocarbonyl]-5-methoxy-6-(4-methylpiperazin-l-yl)-lH- indole, 1 -[(4-bromo-3-methylphenyl)aminocarbonyl]-2,3-dihydro-5-methoxy-6-(4- methylpiperazin- 1 -yl)- 1 H-indole,
  • Preferred salts of the compounds of formula (I) are pharmaceutically acceptable salts. These include acid addition salts such as hydrochlorides, hydrobromides, phosphates, acetates, fumarates, maleates, tartrates, citrates, oxalates, methanesulphonates and p-toluenesulphonates.
  • acid addition salts such as hydrochlorides, hydrobromides, phosphates, acetates, fumarates, maleates, tartrates, citrates, oxalates, methanesulphonates and p-toluenesulphonates.
  • Certain compounds of formula (I) are capable of existing in stereoisomeric forms.
  • the present invention provides a process for the preparation of a compound of formula (I) or a pharmaceutically acceptable salt thereof which comprises:
  • R a -NC( V) (II) in which R a and V are as defined in formula (I) or a protected derivative thereof with a compound of formula (III):
  • Y is -CH 2 - or -O- and L 2 is an appropriate leaving group, with a compound of formula (HI); d) where D is carbon or CH, reacting a compound of formula (VI)
  • D is carbon or CH
  • W, X, R D and R c are as defined in formula (I) and L 2 is an appropriate leaving group and optionally thereafter: • removing any protecting groups
  • reaction in process (a) is conveniently effected in an organic solvent such as dichloromethane.
  • the urea forming agent can be carbonyl diimidazole, triphosgene or phosgene, and carried out in an inert organic solvent such as dimethylformamide, tetrahydrofuran or dichloromethane at ambient or elevated temperature in the presence of a base such as triethylamine or pyridine.
  • the leaving group L 2 may be a halogen e.g. chloro group and the reaction may be carried out in an inert organic solvent such as tetrahydrofuran or dichloromethane at ambient or elevated temperature in the presence of a base such as triethylamine or pyridine.
  • the leaving group L 2 may be a halogen e.g.
  • Carboxylic acid groups can be protected as esters.
  • Aldehyde or ketone groups can be protected as acetals, ketals, thioacetals or thioketals. Deprotection is achieved using standard conditions.
  • 5 HTiA/lB/lD receptor antagonists, and in particular the compounds of the present invention, are expected to be of use in the treatment of CNS disorders such as mood disorders, including depression, seasonal affective disorder and dysthymia; anxiety disorders, including generalised anxiety, panic disorder, agoraphobia, social phobia, obsessive compulsive disorder and post-traumatic stress disorder; memory disorders, including dementia, amnestic disorders and age-associated memory impairment; disorders of eating behaviours, including anorexia nervosa and bulimia nervosa and sleep disorders (including disturbances of Circadian rhythm).
  • CNS disorders include motor disorders such as Parkinson's disease, dementia in Parkinson's disease, neuroleptic- induced Parkinsonism and tardive dyskinesias, as well as other psychiatric disorders.
  • 5WT ⁇ A/IB/ID receptor antagonists, and in particular compounds of the present invention may also be of use in the treatment of endocrine disorders such as hyperprolactinaemia, in the treatment of vasospasm (particularly in the cerebral vasculature) and hypertension, as well as disorders in the gastrointestinal tract where changes in motility and secretion are involved. They may also be of use in the treatment of sexual dysfunction and hypothermia.
  • the present invention also provides a compound of general formula (I) or a physiologically acceptable salt or solvate thereof for use in the treatment of the aforementioned disorders.
  • the invention provides a method of treating the aforementioned disorders which comprises administering an effective amount to a patient in need of such treatment of a compound of general formula (I) or a pharmaceutically acceptable salt or solvate thereof.
  • a compound of general formula (I) or a physiologically acceptable salt or solvate thereof for use in the treatment or prophylaxis of depression.
  • the compounds according to the invention may advantageously be used in conjunction with one or more other therapeutic agents, for instance, different antidepressant agents.
  • the present invention also provides a pharmaceutical composition, which comprises a compound of formula (I) or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
  • a pharmaceutical composition of the invention which may be prepared by admixture, suitably at ambient temperature and atmospheric pressure, is usually adapted for oral, parenteral or rectal administration and, as such, may be in the form of tablets, capsules, oral liquid preparations, powders, granules, lozenges, reconstitutable powders, injectable or infusible solutions or suspensions or suppositories. Orally administrable compositions are generally preferred. Tablets and capsules for oral administration may be in unit dose form, and may contain conventional excipients, such as binding agents, fillers, tabletting lubricants, disintegrants and acceptable wetting agents. The tablets may be coated according to methods well known in normal pharmaceutical practice.
  • Oral liquid preparations may be in the form of, for example, aqueous or oily suspension, solutions, emulsions, syrups or elixirs, or may be in the form of a dry product for reconstitution with water or other suitable vehicle before use.
  • Such liquid preparations may contain conventional additives such as suspending agents, emulsifying agents, non-aqueous vehicles (which may include edible oils), preservatives, and, if desired, conventional flavourings or colorants.
  • fluid unit dosage forms are prepared utilising a compound of the invention or pharmaceutically acceptable salt thereof and a sterile vehicle.
  • the compound depending on the vehicle and concentration used, can be either suspended or dissolved in the vehicle.
  • the compound can be dissolved for injection and filter sterilised before filling into a suitable vial or ampoule and sealing.
  • adjuvants such as a local anaesthetic, preservatives and buffering agents are dissolved in the vehicle.
  • the composition can be frozen after filling into the vial and the water removed under vacuum.
  • Parenteral suspensions are prepared in substantially the same manner, except that the compound is suspended in the vehicle instead of being dissolved, and sterilisation cannot be accomplished by filtration.
  • the compound can be sterilised by exposure to ethylene oxide before suspension in a sterile vehicle.
  • a surfactant or wetting agent is included in the composition to facilitate uniform distribution of the compound.
  • composition may contain from 0.1% to 99% by weight, preferably from 10 to 60% by weight, of the active material, depending on the method of administration.
  • suitable unit doses may be 0.05 to 1000 mg, more suitably 1.0 to 200 mg, and such unit doses may be administered more than once a day, for example two or three a day. Such therapy may extend for a number of weeks or months.
  • Tetrabutylammonium iodide (0.150g) was added, followed by a solution of sodium azide (4.36g, 0.066 mole) in water (75ml) and the mixture was stirred vigorously at 0°C for 3h, then diluted with water (200ml) and the dichloromethane layer separated, dried (Na 2 SO 4 ) and concentrated in vacuo (but not to complete dryness) to afford the acyl azide as a pale orange solid.
  • This material was dissolved in toluene (300ml) and heated under reflux for lh with stirring, then cooled and concentrated in vacuo to afford the title compound as a red brown oil (9.42g, 95%).
  • reaction mixture was allowed to cool, diluted with EtOAc (150 ml), then extracted with 0.5M HCl acid (2 x 100 ml).
  • the acid extract was basified by addition of solid K 2 CO3, then extracted with DCM (2 x 100 ml) and the extract dried (Na 2 SO4) and concentrated in vacuo to afford the title compound as a beige solid (480 mg, 95%).
  • the title compound was prepared from 5 -bromonaphth-1 -ylacetic acid (Bull. Soc. Chim.
  • the 2-butanol was removed in vacuo and the residue partitioned between H 2 O (300 ml) and CH 2 C1 2 (300ml).
  • the CH 2 C1 2 was separated and the aqueous re-extracted with CH 2 C1 2 (3 x 200ml).
  • the organics were combined, dried (Na 2 SO 4 ) and concentrated in vacuo to afford an orange oil, which was purified by column chromatography on silica gel eluting with 0-4% MeOH/CH 2 Cl 2 .
  • the title compound was an orange oil (16.72g, 70%).
  • the aqueous was basified to pHIO with K 2 CO 3 and extracted into CH 2 C1 2 (3 x 300ml). The organics were combined, dried (Na 2 SO 4 ) and concentrated in vacuo to give a dark brown oil, which was purifed by column chromatography on basic alumina eluting with 2% MeOH CH 2 Cl 2 . The title compound was a yellow solid (4.05g, 52%).
  • the title compound was prepared from 4-(2-methyl-pyridin-4-yl)benzoic acid (D48) using a similar procedure to Description 1 to form the isocyanate, then by base hydrolysis using NaOH, to afford the amine as a beige solid (31%).
  • the title compound was prepared from 4-(isoquinolin-4-yl)benzoic acid (D53) using a similar procedure to Description 1.
  • the isocyanate was used as its toluene solution without concentration to the neat compound.
  • the title compound was prepared from 4-carboxyphenylboronic acid and 8- bromoquinoline using a similar procedure to Description 2, obtained as a white solid (65%).
  • the title compound was prepared from 4-(quinolin-8-yl)benzoic acid (D57) using a similar procedure to Description 51.
  • the isocyanate was used as its toluene solution without concentration to the neat compound.
  • the title compound was prepared from 4-(2,6-dimethyl-pyridin-4-yl)benzoic acid (D60) using a similar procedure to Description 1.
  • the isocyanate was used as its toluene solution without concentration to the neat compound.
  • the title compound was prepared from 4-(2,6-dimethyl-pyridin-3-yl)benzoic acid (D61) using a similar procedure to Description 1.
  • the isocyanate was used as its toluene solution without concentration to the neat compound.
  • the title compound was prepared from 8-bromo-5-nitroquinoline (D64) and phenylboronic acid using a similar procedure to Description 2, as an orange/brown solid (99%).
  • the title compound was prepared from 5-nitro-8-phenylquinoline (D65) using a similar procedure to Description 20, as an orange/brown solid (97%).
  • the title compound was prepared from 8-phenylquinoline-4-carboxylic acid (D 85) using a similar procedure to Description 1.
  • the isocyanate was used as its toluene soloution without concentration to the neat compound.
  • the title compound was prepared from 5-(6-methyl-pyridin-2-yl)-l-naphthoic acid (D91) using a similar procedure to Description 1.
  • the isocyanate was not isolated, but used in the next step as its toluene solution.
  • the title compound was prepared from 5-chloro-2,3-dihydro-6-(piperazin-l-yl)-l- trifluoroacetyl-1 H-indole (D94) and di-tert-butyl dicarbonate using a similar procedure to Description 95, as a brown foam (100%).
  • the title compound was prepared from 2,6-dimethyl-4-iodopyridine (Dl 17) and 5- carboxynaphth-1-ylboronic acid (D90) using a similar procedure to Description 2 as a white solid (70%).
  • the title compound was prepared from 5-(2,6-dimethyl-pyridin-4-yl)-l-naphthoic acid (Dl 18) using a similar procedure to Description 1.
  • the isocyanate was not isolated, but used as its toluene solution in the next step.
  • the title compound was prepared from 2-bromothiazole and 4-amino-2- methylphenylboronic acid (D87) using a similar procedure to Description 2 as a yellow/brown oil (65%).
  • the title compound was prepared from 5-(pyrimidin-5-yl)-l-naphthoic acid (D122) using a similar procedure to Decsription 1.
  • the isocyanate was not isolated, but used as its toluene solution in the next step.
  • the title compound was prepared from 5-hydroxynaphth-l-ylamine and 2- bromopyrimidine using a similar procedure to Description 70, as a pale buff coloured powder (58%).
  • the title compound was prepared from 4-(pyridin-4-yl)naphth-l-ylamine (D2) and 2,3- dihydro-6-(4-methylpiperazin-l-yl)-l H-indole (Dl 1) using a similar procedure to Example 4 as a beige solid (50%).
  • the title compound was prepared from 4-(pyridin-4-yl)naphth-l-ylamine (D2) and 2,3- dihydro-5-methyl-6-(4-methylpiperazin-l-yl)-lH-indole (D17) using a similar procedure to Example 4 (52%). This material was converted to its hydrochloride salt as a yellow solid from acetone.
  • Example 14 l-[3-Chloro-4-(pyridin-4-yl)phenylaminocarbonyl]-2,3-dihydro-5-methyl-6-(4- methylpiperazin-1 -yl)-l H-indole
  • the title compound was prepared from 3-chloro-4-(pyridin-4-yl)aniline (D6) and 2,3- dihydro-5-methyl-6-(4-methylpiperazin-l-yl)-lH-indole (D17) using a similar procedure to Example 4 as a white solid (67%).
  • Example 4 as a white solid (33%).
  • the title compound was prepared from 4-(pyridin-4-yl)naphth-l-ylamine (D2) and 2,3- dihydro-6-(4-methylpiperazin-l-yl)-5-trifluoromethyl-lH-indole (D23) using a similar procedure to Example 4 as a beige solid (42%). This material was converted to its hydrochloride salt as a yellow solid from acetone.
  • Example 30 l-[4-(t-Butoxycarbonylamino)phenylaminocarbonyl]-5-chloro-2,3-dihydro-6-(4- methylpiperazin-l-yl)-lH-indole
  • the title compound was prepared from 4-(t-butoxycarbonylamino)aniline (D40) and 5- chloro-2,3-dihydro-6-(4-methylpiperazin-l-yl)-lH-indole (D13) using a similar procedure to Example 4 (29%).
  • the title compound was prepared from 5 -(pyridin-4-yl)naphth-l -ylacetic acid (D25) and 5-chloro-2,3-dihydro-6-(4-methylpiperazin-l-yl)-lH-indole (D13) using a similar procedure to Example 20.
  • the title compound was prepared from 5 -(pyridin-4-yl)naphth-l -ylacetic acid (D25) and 5-bromo-2,3-dihydro-6-(4-methylpiperazin-l-yl)-lH-indole (D15) using a similar procedure to Example 20.
  • the title compound was prepared from 5-chloro-2,3-dihydro-l-(4- iodophenylaminocarbonyl)-6-(4-methylpiperazin-l-yl)-l H-indole (D43) and 2- bromothiazole using a similar procedure to D51 (8%).
  • the title compound was prepared from 5-chloro-2,3-dihydro-l-(4- iodophenylaminocarbonyl)-6-(4-methylpiperazin-l-yl)-l H-indole (D43) and 5- acetylthien-2-ylboronic acid in a similar manner to Description 2, obtained a straw coloured solid (42%).
  • the title compound was prepared from 5-amino-8-phenylquinoline (D66) and 5- chloro-2,3-dihydro-6-(4-methylpiperazin-l-yl)-lH-indole (D13) using a similar procedure to Example 4, as a cream coloured solid (40%).
  • the title compound was prepared from 5-amino-8-phenylquinoline (D66) and 5- bromo-2,3-dihydro-6-(4-methylpiperazin-l-yl)-lH-indole (D15) using a similar procedure to Example 4, as a cream coloured solid (25%).
  • the title compound was prepared from 6-amino-2-(2-phenylethyl)quinoline (D69) and 5-chloro-2,3-dihydro-6-(4-methylpiperazin-l-yl)-lH-indole (D13) using a similar procedure to Example 4, as a white solid (77%).
  • the title compound was prepared from 4-(quinolin-3-yl)phenyl isocyanate (D56) and 5-bromo-2,3-dihydro-6-(4-methylpiperazin-l-yl)-lH-indole (D15) using a similar procedure to Example 2, as an off white solid (6%).
  • the title compound was prepared from 4-(quinolin-3-yl)phenyl isocyanate (D56) and 5-chloro-2,3-dihydro-6-(4-methylpiperazin-l-yl)-lH-indole (D13) using a similar procedure to Example 2, as a light beige solid (10%).
  • the title compound was prepared from 7-amino-2-methyl- 1,2,3,4- tetrahydroisoquinoline (D78) and 5-chloro-2,3-dihydro-6-(4-methylpiperazin-l- yl)-l H-indole (D13) using a similar procedure to Example 4 as a off-white solid (23%).
  • the title compound was prepared from 5-amino-8-phenylquinoline (D66) and 2,3- dihydro-5-methoxy-6-(4-methylpiperazin-l-yl)-lH-indole (intermediate 3 in WO 95/06627) using a similar procedure to Example 4, as a yellow/brown oil (20%). This was converted to the HCl salt as a yellow solid from acetone.
  • Example 80 5-Chloro-2,3-dihydro-6-(4-methylpiperazin-l-yl)-l-[(8-phenylquinolin-4- yl)aminocarbonyl]-lH-indole
  • the title compound was prepared from 8-phenylquinolin-4-yl isocyanate (D86) and 5- chloro-2,3-dihydro-6-(4-methylpiperazin-l-yl)-lH-indole (D13) using a similar procedure to Example 2, as a yellow solid (75%).
  • 6-(4-methylpiperazin-l-yl)-lH-indole The title compound was prepared from 3-methyl-4-(6-methylpyridin-2-yl)aniline (D89) and 2,3-dihydro-5-methoxy-6-(4-methylpiperazin- 1 -yl)- 1 H-indole (intermediate 3 in WO 95/06627) using a similar procedure to Example 4 as a pale yellow foam (84%). This was converted to its hydrochloride salt as a yellow solid from acetone.
  • the title compound was prepared from 5-(6-methylpyridin-2-yl)naphth-l-yl isocyanate (D92) and 2,3-dihydro-5-methoxy-6-(4-methylpiperazin-l-yl)-lH- indole (intermediate 3 in WO 95/06627) using a similar procedure to Example 4 as a pale yellow foam (55%). This was converted to its hydrochloride salt as a pale yellow solid from acetone.
  • the title compound was prepared from 5-(pyridin-4-yl)naphth-l -ylamine (D74) and 5- chloro-2,3-dihydro-6-(4-ethylpiperazin-l-yl)-lH-indole (D97) using a similar procedure to Example 4, as a beige solid (68%).
  • the HCl salt was isolated as a yellow solid from acetone.
  • the title compound was prepared from 4-(pyridizin-3-yl)benzoic acid (D102) using a similar procedure to Description 1 to form the isocyanate followed by addition of 5- chloro-2,3-dihydro-6-(4-methylpiperazin-l-yl)-lH-indole (D13) to afford the urea as a pale yellow solid (7%).
  • the title compound was prepared from 4-(pyridazin-3-yl)benzoic acid (D102) using a similar procedure to Description 1 to form the isocyanate followed by addition of 5- bromo-2,3-dihydro-6-(4-methylpiperazin-l-yl)-l H-indole (D15) to afford the urea as a grey solid (3%).
  • the title compound was prepared from 4-(pyrazin-2-yl)benzoic acid (D103) using a similar procedure to Description 1 to form the isocyanate followed by addition of 5- chloro-2,3-dihydro-6-(4-methylpiperazin-l-yl)-l H-indole (D13) to afford the urea as a pale yellow solid (30%).
  • the title compound was prepared from 4-(pyrazin-2-yl)benzoic acid (D103) using a similar procedure to Description 1 to form the isocyanate followed by addition of 5- bromo-2,3-dihydro-6-(4-methylpiperazin-l-yl)-lH-indole (D15) to afford the urea as a pale yellow solid (49%).
  • the title compound was prepared from 6-phenylnicotinic acid (D104) using a similar procedure to Description 1 to form the isocyanate followed by addition of 5-bromo-2,3- dihydro-6-(4-methylpiperazin-l-yl)-l H-indole (D15) to afford the urea as an off white solid (46%).
  • the title compound was prepared from 5-chloro-2,3-dihydro-l-(4- iodophenylaminocarbonyl)-6-(4-methylpiperazin-l-yl)-lH-indole (D43) and 3- pyridylboronic acid (Chem. Pharm. Bull, 1983, 31(12), 4573) in a similar manner to Description 2, obtained as a pale cream powder (19%).
  • the title compound was prepared from 5-chloro-2,3-dihydro-6-(4-methylpiperazin-l-yl)- lH-indole (D13) and 4-(5-methyloxazol-2-yl)aniline (D107) using a similar procedure to Example 4, obtained as a pale cream powder (63%).
  • the title compound was prepared from 4-(l-methylpyrazol-4-yl)benzoic acid (WO 97/43262) using a similar procedure to Description 1 to form the isocyanate followed by addition of 5-bromo-2,3-dihydro-6-(4-methylpiperazin-l-yl)-lH-indole (D15) to afford the urea as a buff solid (30%).
  • the title compound was prepared from 4-(4-cyano-3-methylphenyl)benzoic acid (D106) using a similar procedure to Description 1 to form the isocyanate followed by addition of 5-bromo-2,3-dihydro-6-(4-methylpiperazin-l-yl)-lH-indole (D15) to afford the urea as a buff solid (28%).
  • the title compound was prepared from 4-(2-methylpyridin-5-yl)benzoic acid (WO 97/43262) using a similar procedure to Description 1 to form the isocyanate followed by addition of 5-chloro-2,3-dihydro-6-(4-methylpiperazin-l-yl)-lH-indole (D13) to afford the urea as a buff solid (2%).
  • the title compound was prepared from 5-chloro-2,3-dihydro-6-(4-methylpiperazin-l-yl)- 1 H-indole (D13) and 5-(3-methyl-l,2,4-oxadiazol-5-yl)naphth-l -ylamine (Di l l) using a similar procedure to Example 4.
  • the title compound was converted to the hydrochloride salt as a pale buff powder (59%).
  • the title compound was prepared from 2,3-dihydro-5-methoxy-6-(4-methylpiperazin-l- yl)-lH-indole (intermediate 3 in WO 95/06627) and 5-(3-methyl-l,2,4-oxadiazol-5- yl)naphth-l -ylamine (Dl 11) in a similar procedure to Example 4.
  • the title compoxmd was converted to the hydrochloride salt as colourless powder (68%).
  • the title compound was prepared from 5-chloro-2,3-dihydro-6-(4-methylpiperazin-l-yl)- lH-indole (D13) and 5-(5-methyloxazol-2-yl)naphth-l-ylamine (D114) in a similar procedure to Example 4, converted to the hydrochloride salt as a pale yellow power (41%).
  • Example 4 using a similar procedure to Example 4 as a beige foam (32%). This foam was converted to its hydrochloride salt as a yellow-brown solid from acetone.
  • ⁇ NMR (HCl salt) 250MHz, d 6 DMSO) ⁇ (ppm): 10.45 (br s, IH), 8.90 (d, 2H), 8.59 (s, IH), 7.83 (d, IH), 7.67 (s, IH), 7.60 (m, 2H), 7.40 (t, IH), 6.92 (s, IH), 4.15 (t, 2H), 3.77 (s, 3H), 3.45 (m, 4H), 3.17 (m, 4H), 2.96 (t, 2H), 2.82 (d, 3H), 2.54 (s, 3H).
  • the title compound was prepared from 3-methyl-4-(pyrimidin-5-yl)aniline (Dl 16) and 5- bromo-2,3-dihydro-6-(4-methylpiperazin-l-yl)-l H-indole (D15) using a similar procedure to Example 4 as a foam (82%). This foam was converted to its hydrochloride salt as an off white solid from acetone.
  • the title compound was prepared from 4-(2,6-dimethylpyridin-4-yl)-3- methylaniline (D88) and 5-bromo-2,3-dihydro-6-(4-methylpiperazin-l-yl)-lH- indole (D15) using a similar procedure to Example 4 as a pale yellow foam (89%). This was converted to its hydrochloride salt as a pale yellow solid from acetone.
  • the title compound was prepared from 4-(2,6-dimethylpyridin-4-yl)-3- methylaniline (D88) and 2,3-dihydro-5-methoxy-6-(4-methylpiperazin-l-yl)-lH- indole (intermediate 3 in WO 95/06627) using a similar procedure to Example 4 as a pale yellow foam (95%). This was converted to its hydrochloride salt as a yellow solid from acetone.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La présente invention concerne des composés représentés par la formule (I), leurs procédés de préparation, leur utilisation comme agents CNS, dans laquelle Ra est un groupe représenté par la formule (i) ou P1 est un phényle, un aryle bicyclique, un noyau hétérocyclique de 5 à 7 chaînons contenant 1 à 3 hétéroatomes sélectionnés dans le groupe constitué d'oxygène, d'azote et de soufre, or un noyau hétérocyclique bicyclique contenant 1 à 3 hétéroatomes sélectionnés dans le groupe constitué d'oxygène, d'azote et de soufre; R1 et hydrogène, halogène, C¿1-6?alkyle, C3-6cycloalkyle, COC1-6alkyle, C1-6alkoxy, hydroxy, hydroxyC1-6alkyle, hydroxyC1-6alcoxy, C1-6alcoxyC1-6alcoxy, C1-6alkanoyl, nitro, trifluorométhyl, cyano, SR?9, SOR9, SO¿2R9, SO2NR?1OR11, CO¿2R?10, CONR10R11, CO¿2NR?10R11, CONR10(CH¿2)cCO2R11, (CH2)cNR?10R11, (CH¿2)cCONR?10R11, (CH¿2)cNR?10COR11, (CH¿2)cCO2C1-6alkyl, CO2(CH2)cOR?10, NR10R11, NR10CO¿2R?11, NR10CONR10R11, CR10=NOR11, NR10COOR11, CNR10=NOR11, où R10 et R11¿ sont indépendamment hydrogen ou C¿1-6?alkyle et c est compris entre 1 et 4; R?2¿ est hydrogène, halogène, C¿1-6?alkyle, C3-6cycloalkyle, C3-6cycloalcényl, C1-6alcoxy, acyle, aryle, acyloxy, hydroxy, nitro, trifluorométhyl, cyano, CO2R?10, CONR10R11, NR10R11 où R10 et R11¿ sont tels que définis pour R1; a est 1, 2 ou 3; ou Ra est un groupe représenté par la formule (ii), dans laquelle P2 et P3 sont indépendamment un phényl, un aryle bicyclique, un noyau hétérocyclique de 5 à 7 chaînons contenant 1 à 3 hétéroatomes sélectionnés dans le groupe constitué d'oxygène, d'azote et de soufre ou un groupe hétérocyclique bicyclique contenant 1 à 3 hétéroatomes sélectionnés dans le groupe constitué d'oxygène, d'azote ou de soufre; A est une liaison ou oxygène, S(O)¿m? où m est compris entre 0 et 2, carbonyl, CH2 ou NR?4 où R4¿ est hydrogène ou C¿1-6?alkyle; R?1¿ est tel que défini ci-dessus pour la formule (I) ou R1 est un noyau hétérocyclique de 5 à 7 chaînons éventuellement substitué contenant 1 à 3 hétéroatomes sélectionnés dans le groupe constitué d'oxygène, d'azote ou de soufre; R2 et R3 sont indépendamment hydrogène, halogène, C¿1-6?alkyle, C3-6cycloalkyle, C3-6cycloalcényle, C1-6alcoxy, acyle, aryle, acyloxy, hydroxy, nitro, trifluorométhyl, cyano, CO2R?10, CONR10R11, NR10R11 où R10 et R11¿ sont tels que définis pour R1; et a et b sont indépendamment 1, 2 ou 3; Y est -NH-, NR5 où R5 est C¿1-6?alkyle, ou Y est -CH2- ou -O-; V est oxygène ou soufre; D est azote, carbone ou un groupe CH; W est (CR?16R17)¿t où t est 2, 3 ou 4 et R?16 et R17¿ sont indépendamment hydrogène où C¿1-6?alkyle ou W est (CR?16R17)¿u-J où u est 0, 1, 2 ou 3 et J est oxygène, soufre, CR?16=CR17, CR16=N, =CR16O, =CR16¿S ou =CR16-NR17; X est azote ou carbone; Rb est hydrogène, halogène, hydroxy, C¿1-6?alkyle, trifluorométhyl, C1-6alcoxy, C2-6alcényl, C3-7cycloalkyle éventuellement substitué par C1-4alkyle, ou aryle; R?c¿ est hydrogène ou C¿1-6?alkyle; et ..... est une liaison simple lorsque X est azote ou une liaison simple ou double lorsque X est carbone.
EP98921462A 1997-04-18 1998-04-14 Derives indoliques a activite de recepteur antagoniste 5ht1a, 5ht1b, 5ht1d Withdrawn EP0975593A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB9707829 1997-04-18
GBGB9707829.9A GB9707829D0 (en) 1997-04-18 1997-04-18 Novel compounds
GB9801882 1998-01-29
GBGB9801882.3A GB9801882D0 (en) 1998-01-29 1998-01-29 Novel compounds
PCT/EP1998/002262 WO1998050358A1 (fr) 1997-04-18 1998-04-14 Derives indoliques a activite de recepteur antagoniste 5ht1a, 5ht1b, 5ht1d

Publications (1)

Publication Number Publication Date
EP0975593A1 true EP0975593A1 (fr) 2000-02-02

Family

ID=26311401

Family Applications (1)

Application Number Title Priority Date Filing Date
EP98921462A Withdrawn EP0975593A1 (fr) 1997-04-18 1998-04-14 Derives indoliques a activite de recepteur antagoniste 5ht1a, 5ht1b, 5ht1d

Country Status (17)

Country Link
EP (1) EP0975593A1 (fr)
JP (1) JP2001524116A (fr)
KR (1) KR20010006487A (fr)
CN (1) CN1260781A (fr)
AR (1) AR013076A1 (fr)
AU (1) AU732863B2 (fr)
BR (1) BR9809092A (fr)
CA (1) CA2288662A1 (fr)
CO (1) CO4950608A1 (fr)
HU (1) HUP0001123A3 (fr)
IL (1) IL132409A0 (fr)
NO (1) NO995065L (fr)
NZ (1) NZ500252A (fr)
PL (1) PL336317A1 (fr)
TR (1) TR199902590T2 (fr)
TW (1) TW509687B (fr)
WO (1) WO1998050358A1 (fr)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9725931D0 (en) * 1997-12-05 1998-02-04 Smithkline Beecham Plc Novel compounds
AU753360B2 (en) 1998-07-31 2002-10-17 Nippon Soda Co., Ltd. Phenylazole compounds, process for producing the same and drugs for hyperlipemia
GB9827882D0 (en) * 1998-12-17 1999-02-10 Smithkline Beecham Plc Novel compounds
UA62015C2 (en) 1998-12-28 2003-12-15 Pfizer Prod Inc Benzoizoxazol derivatives, a pharmaceutical composition (variants) based thereon (variants) and a method for treatment (variants)
GB9912417D0 (en) 1999-05-28 1999-07-28 Pfizer Ltd Compounds useful in therapy
GB9912413D0 (en) * 1999-05-28 1999-07-28 Pfizer Ltd Compounds useful in therapy
CA2378047A1 (fr) * 1999-07-15 2001-01-25 Methvin Isaac Composes heterocycliques destines au traitement de la migraine
BR0014279A (pt) * 1999-09-25 2002-05-21 Smithkline Beecham Plc Derivados de piperazina como antagonistas 5-ht1b
ES2234683T3 (es) * 1999-11-05 2005-07-01 Smithkline Beecham Plc Derivados de isoquinolina y quinazolina con actividad combinada sobre los receptores 5ht1a, 5ht1b y 5ht1d.
GB9926303D0 (en) * 1999-11-05 2000-01-12 Smithkline Beecham Plc Novel compounds
DE10051981A1 (de) 2000-10-20 2002-05-02 Bayer Ag Substituierte Phenyluracile
GB0106419D0 (en) * 2001-03-15 2001-05-02 Smithkline Beecham Plc Novel compounds
GB0106586D0 (en) * 2001-03-16 2001-05-09 Smithkline Beecham Plc Novel compounds
SK16052003A3 (en) * 2001-06-07 2004-10-05 Hoffmann La Roche New indole derivatives with 5-HT6 receptor affinity
TW200403223A (en) 2002-02-15 2004-03-01 Glaxo Group Ltd Novel compounds
ATE316523T1 (de) 2002-05-13 2006-02-15 Hoffmann La Roche Benzoxazinderivate als 5-ht6-modulatoren und deren verwendungen
CA2547764A1 (fr) 2003-12-09 2005-06-30 F.Hoffmann-La Roche Ag Derives de benzoxazine et utilisations de ceux-ci
JP2011506445A (ja) * 2007-12-13 2011-03-03 アムジエン・インコーポレーテツド γ−セクレターゼ調節剤
BR112012024380A2 (pt) 2010-03-25 2015-09-15 Glaxosmithkline Llc compostos químicos
GB201106817D0 (en) 2011-04-21 2011-06-01 Astex Therapeutics Ltd New compound
CN102924330A (zh) * 2012-09-03 2013-02-13 华东理工大学 一种规模化制备5-氨基-1-萘腈的方法
GB201218850D0 (en) 2012-10-19 2012-12-05 Astex Therapeutics Ltd Bicyclic heterocycle compounds and their uses in therapy
GB201218864D0 (en) 2012-10-19 2012-12-05 Astex Therapeutics Ltd Bicyclic heterocycle compounds and their uses in therapy
US9980973B2 (en) 2012-10-19 2018-05-29 Astex Therapeutics Limited Bicyclic heterocycle compounds and their uses in therapy
GB201218862D0 (en) 2012-10-19 2012-12-05 Astex Therapeutics Ltd Bicyclic heterocycle compounds and their uses in therapy
CN103467374A (zh) * 2013-08-30 2013-12-25 江苏弘和药物研发有限公司 一种8-溴-4-羧基喹啉的合成方法
WO2015092420A1 (fr) 2013-12-20 2015-06-25 Astex Therapeutics Limited Composés hétérocycliques bicycliques et leurs utilisations thérapeutiques
CN115197099A (zh) * 2022-05-30 2022-10-18 安徽昊帆生物有限公司 N-Boc-1，4-苯二胺的制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9119920D0 (en) * 1991-09-18 1991-10-30 Glaxo Group Ltd Chemical compounds
DE69232003T2 (de) * 1991-09-18 2002-04-25 Glaxo Group Ltd., Greenford Benzanilidderivate als 5-HT1D-Antagonisten
GB9119932D0 (en) * 1991-09-18 1991-10-30 Glaxo Group Ltd Chemical compounds
WO1995004729A1 (fr) * 1993-08-06 1995-02-16 Smithkline Beecham Plc Derives amides employes comme antagonistes du recepteur 5ht1d
DE69411176T2 (de) * 1993-08-20 1998-11-12 Smithkline Beecham Plc Amide und harnstoffderivate als 5ht1d rezeptor antagonisten
WO1995006637A1 (fr) * 1993-09-03 1995-03-09 Smithkline Beecham Plc Nouveaux derives d'indole et d'indoline en tant qu'antagonistes du recepteur de 5ht1d

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9850358A1 *

Also Published As

Publication number Publication date
NO995065D0 (no) 1999-10-15
CA2288662A1 (fr) 1998-11-12
PL336317A1 (en) 2000-06-19
HUP0001123A2 (hu) 2001-04-28
WO1998050358A1 (fr) 1998-11-12
BR9809092A (pt) 2002-01-22
HUP0001123A3 (en) 2002-04-29
NZ500252A (en) 2001-07-27
KR20010006487A (ko) 2001-01-26
TR199902590T2 (xx) 2000-06-21
AU7431098A (en) 1998-11-27
IL132409A0 (en) 2001-03-19
CN1260781A (zh) 2000-07-19
AR013076A1 (es) 2000-12-13
NO995065L (no) 1999-10-15
AU732863B2 (en) 2001-05-03
JP2001524116A (ja) 2001-11-27
CO4950608A1 (es) 2000-09-01
TW509687B (en) 2002-11-11

Similar Documents

Publication Publication Date Title
WO1998050358A1 (fr) Derives indoliques a activite de recepteur antagoniste 5ht1a, 5ht1b, 5ht1d
JP6466171B2 (ja) 新規アミン誘導体またはその塩
KR101477553B1 (ko) 이소인돌론 화합물 및 대사성 글루타메이트 수용체증강제로서 이들의 용도
RU2345070C2 (ru) Производные аминоиндазолов в качестве лекарственных средств, способ их получения и содержащие их фармацевтические композиции
JP5675359B2 (ja) Ｄｇａｔ１阻害剤としてのオキサジアゾールおよびオキサゾール置換ベンゾイミダゾールおよびインドール誘導体
JP2005521698A (ja) 新規な三環式化合物
EP1414442A1 (fr) 3-arylsulfonyl-7-piperazinyl- indols, -benzofurans et benzothiophenes a affinite avec les recepteurs 5-ht6 pour le traitement de troubles du snc
JP5236002B2 (ja) ヘテロ環化合物及びその医薬組成物
CN1345318A (zh) 与多巴胺d3受体具有亲和力的三唑化合物
TW201643153A (zh) 溴結構域抑制劑
CN105934425B (zh) Ebna1抑制剂和其使用方法
EP2021330A2 (fr) Modulateurs des récepteurs vr1 dérivés du benzimidazole
JP2009508872A (ja) カルバゾール誘導体
JP5746471B2 (ja) ベンゾイミダゾール系ｔｒｐｖ１阻害剤
CN102574786A (zh) 二氢乳清酸脱氢酶抑制剂
EP0548813A1 (fr) Dérivés antimigraines de 4-pyrimidine- et pyridine-indol-3-ylalkylpiperazines
WO1997037989A1 (fr) Derives indoles en tant qu'antagonistes du recepteur de 5-ht
JPWO2012102255A1 (ja) インドール誘導体、またはその薬理学的に許容される塩
AU2014294866A1 (en) Novel derivatives of indole and pyrrole, method for the production thereof and pharmaceutical compositions containing same
CN115667216A (zh) 用于治疗癌症的作为tead蛋白和hippo-yap1/taz信号传导级联抑制剂的(1h-吲哚-5-基)丙烯酰胺衍生物
JPWO2011013624A1 (ja) インドール誘導体、またはその薬理学的に許容される塩
TWI343375B (en) Indolinone derivatives, substituted in the 6-position, their preparation and their use as medicaments
WO1996004251A1 (fr) Compose heterocyclique
AU673098B2 (en) Antimigraine cyclobutenedione derivatives of indolylalkyl-pyridinyl and pyrimidinylpiperazines
EP1742947A1 (fr) Derives de pyridoindolone substitues en -6, leur preparation, leur application en therapeutique.

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19991022

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: SI PAYMENT 19991022

17Q First examination report despatched

Effective date: 20020502

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: SMITHKLINE BEECHAM PLC

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20021113

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1026695

Country of ref document: HK